Sitafloxacin

Sitafloxacin (DU6859a) is a potent, orally active fluoroquinolone antibiotic. Sitafloxacin shows antichlamydial activity and antibacterial activities against a broad range of gram-positive and gram-negative bacteria, including anaerobic bacteria, as well as against atypical pathogens. Sitafloxacin can be used for the research of respiratory tract infection and urinary tract infection^[1][2]. In Vitro: Sitafloxacin (DU6859a) shows antibacterial activities with MIC of 0.03, 0.12, 0.06 mg/L for wild-type ATCC 49619, gyrA mutant SP39, parC mutant 1026523 streptococcus pneumoniae stran, respectively^[1].
Sitafloxacin (DU6859a) shows antibacterial activities for quinolone-susceptible strains of streptococcus pneumoniae with MIC of 0.03, 0.03 mg/L for EG 00093 and EG 00218 strain, respectively^[1].
Sitafloxacin (DU6859a) shows inhibition for DNA gyrase and topoisomerase IV (TopoIV) with >IC₅₀s of 4.38, 3.12 mg/L, respectively^[1]. In Vivo: Sitafloxacin (DU-6859a) (12.5-100 mg/kg; i.g.; daily for 4 weeks; BALB/c female mice) has antibacterial activity. M. ulcerans cells could be isolated from the inoculated footpads and there was no evidence of footpad swelling^[2].